Skip to content

Study · Animal study (in vivo) · mouse · 1998

2 results

Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)

Marcotte ER, Chugh A, Mishra RK, Johnson RL

Peptides1 Jan 1998Cited by 22 (Europe PMC)

PMID9493876 (opens in a new tab)DOI10.1016/s0196-9781(97)00321-5 (opens in a new tab)PepBankPUB-09493876
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-lesioned mice, MIF‑1 was less potent and efficacious than PAOPA in preserving dopamine levels.

    In plain wordsIn mice with MPTP lesions, MIF‑1 preserved dopamine less effectively than PAOPA.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseDopamine preservation
    Study

    mousen: not reported in source

    MPTP-lesioned C57 BL/6 mice
    Comparator
    PAOPA
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    PAOPA was found to be more potent and efficacious that MIF-1 in sparing dopamine and its metabolite levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
    1 context sentence
    Summary · context
    Given the ability of MIF-1 to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in C57 BL/6 mice, the present study was undertaken to evaluate the neuroprotective effect of PAOPA in this model.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-lesioned mice, MIF‑1 was less potent and efficacious than PAOPA in preserving dopamine metabolite levels.

    In plain wordsIn mice with MPTP lesions, MIF‑1 preserved dopamine metabolites less effectively than PAOPA.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseDopamine metabolite preservation
    Study

    mousen: not reported in source

    MPTP-lesioned C57 BL/6 mice
    Comparator
    PAOPA
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    PAOPA was found to be more potent and efficacious that MIF-1 in sparing dopamine and its metabolite levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
    1 context sentence
    Summary · context
    Given the ability of MIF-1 to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in C57 BL/6 mice, the present study was undertaken to evaluate the neuroprotective effect of PAOPA in this model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.